Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Eric J. Small,Fred Saad,Simon Chowdhury,Stéphane Oudard,Boris Hadaschik,Julie N. Graff,David Olmos,Paul N. Mainwaring,Ji Youl Lee,Hiroji Uemura,Peter De Porre,Andressa Smith,Sabine Brookman-May,Susan Li,Ke Zhang,Oliver Brendan Rooney,Angela Lopez-Gitlitz,Matthew R. Smith

Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

2020

Eric J. Small
Fred Saad
Simon Chowdhury
Stéphane Oudard
Boris Hadaschik
Julie N. Graff
David Olmos
Paul N. Mainwaring
Ji Youl Lee
Hiroji Uemura
Peter De Porre
Andressa Smith
Sabine Brookman-May
Susan Li
Ke Zhang
Oliver Brendan Rooney
Angela Lopez-Gitlitz
Matthew R. Smith

5516Background: SPARTAN evaluated APA vs PBO in pts with nmCRPC and a prostate-specific antigen doubling time of ≤ 10 mo receiving androgen deprivation therapy (ADT). At primary end point analysis ...

Keywords:

Oncology
Apalutamide
in patient
Prostate cancer
castration resistant
Internal medicine
Pathology
Placebo
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations